Showing results (231-240 of 294) with videos related to

Sort By:
Pageof 30
Clinical Pharmacology and Therapeutics|January 31, 2008
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populationsS P Myrand, K Sekiguchi, M Z Man, et al.
JAMA|October 23, 1997
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testingD Shattuck-Eidens, A Oliphant, M McClure, et al.
Cancer Research|October 23, 1997
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressorD H Teng, W L Perry, J K Hogan, et al.
Cancer Research|December 11, 1997
MMAC1/PTEN mutations in primary tumor specimens and tumor cell linesD H Teng, R Hu, H Lin, et al.
European Journal of Medicinal Chemistry|May 28, 2018
SAR studies on truxillic acid mono esters as a new class of antinociceptive agents targeting fatty acid binding proteinsSu Yan, Matthew W Elmes, Simon Tong, et al.
Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases|December 6, 2021
[Prognosis and related risk factors of acute respiratory distress syndrome in elder patients]X Huang, D W Wu, H N Lu, et al.
Cancer Discovery|June 8, 2017
Secondary Somatic Mutations Restoring <i>RAD51C</i> and <i>RAD51D</i> Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian CarcinomaOlga Kondrashova, Minh Nguyen, Kristy Shield-Artin, et al.
Nature Genetics|February 15, 2001
A candidate prostate cancer susceptibility gene at chromosome 17pS V Tavtigian, J Simard, D H Teng, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 2012
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumorsStephen B Willingham, Jens-Peter Volkmer, Andrew J Gentles, et al.
Science (New York, N.Y.)|January 13, 2018
Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomicsAnnie N Cowell, Eva S Istvan, Amanda K Lukens, et al.
Pageof 30